Baseline characteristics of mycophenolate treatment episodes in analysis 1 (proportion of treatment initiations that coincide with pregnancy)
| Before propensity score weighting | After propensity score weighting | |||||
| Covariates | MG period (n=15 017) | REMS period (n=9260) | ASD | MG period (n=15 018) | REMS period (n=9259) | ASD |
| Age at index date (%) | ||||||
| 15–19 | 1541 (10.3) | 887 (9.6) | 0.02 | 1504 (10.0) | 925 (10.0) | 0.00 |
| 20–29 | 3350 (22.3) | 2196 (23.7) | 0.03 | 3430 (22.8) | 2119 (22.9) | 0.00 |
| 30–39 | 5921 (39.4) | 3404 (36.8) | 0.05 | 5778 (38.5) | 3567 (38.5) | 0.00 |
| 40–44 | 4205 (28.0) | 2773 (29.9) | 0.04 | 4306 (28.7) | 2647 (28.6) | 0.00 |
| Indications* (%) | ||||||
| Tissue disorders† | 6762 (45.0) | 4468 (48.2) | 0.06 | 6944 (46.2) | 4279 (46.2) | 0.00 |
| Kidney transplant | 3263 (21.7) | 1961 (21.2) | 0.01 | 3233 (21.5) | 1993 (21.5) | 0.00 |
| Other solid organ transplants | 1024 (6.8) | 623 (6.7) | 0.00 | 1019 (6.8) | 630 (6.8) | 0.00 |
| Skin disorders‡ | 1040 (6.9) | 723 (7.8) | 0.03 | 1090 (7.3) | 674 (7.3) | 0.00 |
| Nephrology disorders | 1145 (7.6) | 627 (6.8) | 0.03 | 1097 (7.3) | 677 (7.3) | 0.00 |
| Myasthenia gravis | 380 (2.5) | 221 (2.4) | 0.01 | 372 (2.5) | 232 (2.5) | 0.00 |
| Autoimmune hepatitis | 332 (2.2) | 210 (2.3) | 0.00 | 335 (2.2) | 207 (2.2) | 0.00 |
| Multiple sclerosis | 290 (1.9) | 122 (1.3) | 0.05 | 256 (1.7) | 159 (1.7) | 0.00 |
| Rheumatoid arthritis | 989 (6.6) | 587 (6.3) | 0.01 | 972 (6.5) | 594 (6.4) | 0.00 |
| Arteritis | 552 (3.7) | 261 (2.8) | 0.05 | 505 (3.4) | 315 (3.4) | 0.00 |
| Iridocyclitis | 276 (1.8) | 177 (1.9) | 0.01 | 282 (1.9) | 175 (1.9) | 0.00 |
| Blood disorder/bone marrow transplant | 223 (1.5) | 107 (1.2) | 0.03 | 214 (1.4) | 116 (1.2) | 0.00 |
| Neuroinflammatory disorder | 186 (1.2) | 95 (1.0) | 0.02 | 183 (1.2) | 99 (1.1) | 0.02 |
| Unknown | 1474 (9.8) | 804 (8.7) | 0.04 | 1408 (9.4) | 868 (9.4) | 0.01 |
| Recent mycophenolate treatment episode | 5218 (34.7) | 4077 (44.0) | 0.19 | 5751 (38.3) | 3546 (38.3) | 0.00 |
| Charlson Comorbidity Index (%) | ||||||
| 0–1 | 7629 (50.8) | 4830 (52.2) | 0.03 | 7313 (48.7) | 4509 (48.7) | 0.00 |
| >1 | 7388 (49.2) | 4430 (47.8) | 0.03 | 7705 (51.3) | 4750 (51.3) | 0.00 |
| Depression | 1470 (9.8) | 1013 (10.9) | 0.04 | 1542 (10.3) | 951 (10.3) | 0.00 |
| Use of teratogenic drugs (%) | 7846 (52.2) | 4596 (49.6) | 0.05 | 7700 (51.3) | 4751 (51.3) | 0.00 |
| Insurance holder status (%) | ||||||
| Employee | 7751 (51.6) | 4492 (48.5) | 0.06 | 7571 (50.4) | 4664 (50.4) | 0.00 |
| Spouse | 4280 (28.5) | 2568 (27.7) | 0.02 | 4230 (28.2) | 2609 (28.2) | 0.00 |
| Other dependent | 2986 (19.9) | 2200 (23.8) | 0.09 | 3216 (21.4) | 1986 (21.4) | 0.00 |
| Region of residence | ||||||
| Northeast | 2218 (14.8) | 1492 (16.1) | 0.04 | 2290 (15.2) | 1411 (15.2) | 0.00 |
| North central | 3255 (21.7) | 1822 (19.7) | 0.05 | 3139 (20.9) | 1932 (20.9) | 0.00 |
| South | 6170 (41.1) | 3757 (40.6) | 0.01 | 6146 (40.9) | 3792 (40.9) | 0.00 |
| West | 3144 (20.9) | 1967 (21.2) | 0.01 | 3162 (21.1) | 1950 (21.1) | 0.00 |
| Unknown | 230 (1.5) | 222 (2.4) | 0.06 | 281 (1.9) | 173 (1.9) | 0.00 |
*Indications are not mutually exclusive.
†Tissue disorders include systemic lupus erythematosus, sclerosis and other tissue conditions.
‡Skin disorders include psoriasis, lupus and other skin conditions.
ASD, absolute standardised difference; MG, medication guide; REMS, Risk Evaluation and Mitigation Strategy.